Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Phanes Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners but 2 distinct art units, indicating examiner-level distribution within a narrower art-unit footprint.
FAUST, AMBER KATHLEEN is the busiest examiner, with 1 pending action. Counsel should track each matter separately while checking for issues that may recur across the 2 art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997755 | Anti-Tumor Associated Antigen Antibodies and Uses Thereof | GEORGE, DENNIS CHERIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760394 | Antibodies Conjugated with Fatty Acid Molecules and Uses Thereof | MELCHIOR, JAMES RYLAND | 37d overdue |
| 17997755 | Anti-Tumor Associated Antigen Antibodies and Uses Thereof | GEORGE, DENNIS CHERIAN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17997755 | Anti-Tumor Associated Antigen Antibodies and Uses Thereof | GEORGE, DENNIS CHERIAN | 1644 | §102§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17760394 | Antibodies Conjugated with Fatty Acid Molecules and Uses Thereof | MELCHIOR, JAMES RYLAND | 1644 | §103§112DP | Non-Final OA | 37d overdue | Pending | Aug 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhanes Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Dennis Cherian George has the most, with 1 of Phanes Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
